Literature DB >> 30032936

Post-hoc analysis of two clinical trials examining Customized Adherence Enhancement plus long acting injectable antipsychotic (CAE-L) in high-risk individuals with serious mental illness.

Christine M Collins1, Michelle E Aebi1, Jennifer B Levin1, Curtis Tatsuoka2, Kristin A Cassidy1, Martha Sajatovic3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30032936     DOI： 10.1016/j.schres.2018.07.024

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  3 in total

1.  A customized adherence enhancement program combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania: A pilot study methodological report.

Authors:  Jessie Mbwambo; Sylvia Kaaya; Isaac Lema; Carol Blixen; Kristin A Cassidy; Jennifer B Levin; Martha Sajatovic
Journal:  Heliyon       Date:  2019-06-07

2.  An interventional pilot of customized adherence enhancement combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania.

Authors:  Jessie Mbwambo; Sylvia Kaaya; Isaac Lema; Christopher J Burant; Catherine Magwiza; Kim Madundo; Godwin Njiro; Carol E Blixen; Kristin A Cassidy; Jennifer B Levin; Martha Sajatovic
Journal:  BMC Psychiatry       Date:  2022-01-27       Impact factor: 3.630

3.  Community perceptions of barriers to management of chronic psychotic disorders and knowledge and attitudes about long-acting injectable antipsychotic medication: qualitative study in Dar es Salaam, Tanzania.

Authors:  Carol Blixen; Isaac Lema; Jessie Mbwambo; Sylvia Kaaya; Jennifer B Levin; Martha Sajatovic
Journal:  BJPsych Open       Date:  2020-03-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.